Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia

July 16, 2020 updated by: aijun xu, Tongji Hospital

Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia

To analyze the intubation with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients with severe covid-19 pneumonia.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

To analyze the intubation time, intubation condition, intubation process, intubation times and success rate of patients with severe covid-19 pneumonia, the infection rate of anesthesiologist after intubation, the degree of respiratory improvement and survival rate of patients, and summarizes the experience of how to avoid the infection of anesthesiologist and ensure the safety of patients with severe covid-19 pneumonia.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430000
        • Tongji Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Severe and critical patients with covid-19 pneumonia in urgent need of tracheal intubation

Description

Inclusion Criteria:

  • Wuhan residents;
  • novel coronavirus pneumonia was found to be characterized by fever and cough. Laboratory tests revealed leukocyte or lymphocyte decrease, chest CT examination showed viral pneumonia changes, and was diagnosed as COVID-19 pneumonia according to the national health and Health Committee's new coronavirus pneumonia diagnosis and treatment plan (trial version fifth Revision).
  • Severe and critical patients with covid-19 pneumonia in urgent need of tracheal intubation;
  • Sign informed consent.

Exclusion Criteria:

  • Suspected patients with covid-19 pneumonia;
  • Patients who need emergency endotracheal intubation due to other causes of respiratory failure;
  • The family refused to sign the informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Success rate of intubation
Time Frame: the time span between 1hour before intubation and 24h after intubation
The data of Success rate of intubation with severe COVID-19 pneumonia patients
the time span between 1hour before intubation and 24h after intubation
Infection rate of Anesthesiologist
Time Frame: the time span between 1hour before intubation and 14days after intubation
Infection rate of Anesthesiologist who performed the endotracheal intubation for severe COVID-19 pneumonia patients
the time span between 1hour before intubation and 14days after intubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Extubation time
Time Frame: the time span between 1hour before intubation and 30days after intubation
Extubation time of intubated severe COVID-19 pneumonia patients
the time span between 1hour before intubation and 30days after intubation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tongji Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

August 7, 2020

Primary Completion (ANTICIPATED)

December 30, 2020

Study Completion (ANTICIPATED)

December 30, 2020

Study Registration Dates

First Submitted

February 26, 2020

First Submitted That Met QC Criteria

March 4, 2020

First Posted (ACTUAL)

March 6, 2020

Study Record Updates

Last Update Posted (ACTUAL)

July 20, 2020

Last Update Submitted That Met QC Criteria

July 16, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • COVEI

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on severe covid-19 pneumonia with ET

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe